Abstract
The activity of GR69153, a novel catechol-substituted cephalosporin, was compared with those of ceftazidime and ceftriaxone in a multicenter study against 5,203 fresh clinical isolates of gram-negative and gram-positive bacteria. GR69153 was generally very active at concentrations equivalent to or two- to fourfold lower than those of ceftazidime and ceftriaxone against gram-negative bacilli other than Citrobacter freundii, Enterobacter cloacae, and Xanthomonas maltophilia. Against Pseudomonas aeruginosa, MICs of GR69153 and ceftazidime for 50% of isolates tested (MIC50s) were, respectively, 1 and 2 micrograms/ml; the corresponding MIC90s were 4 and 16 micrograms/ml. Although MIC50s of GR69153 for staphylococci were two- to eightfold lower than those of ceftazidime or ceftriaxone, MIC90s against staphylococci and enterococci were greater than or equal to 16 micrograms/ml for all three compounds. Quality control MIC ranges for reference strains are proposed for the broth microdilution method on the basis of the GR69153 data derived from this multicenter study.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Erwin M. E., Jones R. N., Barrett M. S., Briggs B. M., Johnson D. M. In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin. Antimicrob Agents Chemother. 1991 May;35(5):929–937. doi: 10.1128/aac.35.5.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Silley P., Griffiths J. W., Monsey D., Harris A. M. Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system. Antimicrob Agents Chemother. 1990 Sep;34(9):1806–1808. doi: 10.1128/aac.34.9.1806. [DOI] [PMC free article] [PubMed] [Google Scholar]